Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
Open Access
- 19 September 2022
- Vol. 14 (18), 4543
- https://doi.org/10.3390/cancers14184543
Abstract
The prognosis and quality of life of HER2 breast cancer patients have significantly improved due to the crucial clinical benefit of various anti-HER2 targeted therapies. However, HER2 tumors can possess or develop several resistance mechanisms to these treatments, thus leaving patients with a limited set of additional therapeutic options. Fortunately, to overcome this problem, in recent years, multiple different and complementary approaches have been developed (such as antibody–drug conjugates (ADCs)) that are in clinical or preclinical stages. In this review, we focus on emerging strategies other than on ADCs that are either aimed at directly target the HER2 receptor (i.e., novel tyrosine kinase inhibitors) or subsequent intracellular signaling (e.g., PI3K/AKT/mTOR, CDK4/6 inhibitors, etc.), as well as on innovative approaches designed to attack other potential tumor weaknesses (such as immunotherapy, autophagy blockade, or targeting of other genes within the HER2 amplicon). Moreover, relevant technical advances such as anti-HER2 nanotherapies and immunotoxins are also discussed. In brief, this review summarizes the impact of novel therapeutic approaches on current and future clinical management of aggressive HER2 breast tumors.Funding Information
- Ministerio de Ciencia y Tecnología (MICINN-AEI, PID2019-104644RB-I00)
- ISCIII (CIBERONC, CB16/12/00295)
- AECC (FCAECC PROYE19036MOR, GCTRA18014MATI)
This publication has 218 references indexed in Scilit:
- Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumabJournal of Translational Medicine, 2012
- Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?The Breast, 2012
- Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast CancerMolecular Cancer Therapeutics, 2011
- Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibitionOncogene, 2011
- p95HER2 and Breast CancerCancer Research, 2011
- Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthOncogene, 2009
- A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and MetastasisMolecular and Cellular Biology, 2009
- A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerProceedings of the National Academy of Sciences of the United States of America, 2006
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004